Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT01496053
• Date of registration: 15/12/2011
• Prospective Registration: No
• Primary sponsor: Oslo University Hospital
• Public title: Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)
• Scientific title: Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study
• Date of first enrolment: December 2011
• Target sample size: 100
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT01496053
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).
• Phase: Phase 2/Phase 3

Countries of recruitment

Norway

Contacts

• Name: Egil Johnson, MD. Phd
• Affiliation: Ullevaal University Hospital

Key inclusion & exclusion criteria

Inclusion Criteria:

- moderate disease

Exclusion Criteria:

- serious disease,

- biological treatment,

- pregnancy.



Age minimum: 18 Years
Age maximum: 60 Years
Gender: All

Health Condition(s) or Problem(s) studied

Inflammatory Bowel Disease

Ulcerative Colitis

Crohn's Disease

Intervention(s)

Dietary Supplement: AndoSan

Dietary Supplement: Sugar Extract

Primary Outcome(s)

Reduction in biochemical blood parameters (pro-inflammatory cytokines) [Time Frame: 21 days]

Secondary Outcome(s)

Reduction of calprotectin in feces. [Time Frame: 21 days]

Clinical symptom score. [Time Frame: 21 days]

Secondary ID(s)

AbM2012-IBD

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

ImmunoPharma AS